keyword
MENU ▼
Read by QxMD icon Read
search

Borderline ovarian carcinoma

keyword
https://www.readbyqxmd.com/read/28427435/prohibitin-targeting-peptide-coupled-to-ovarian-cancer-luteinization-and-tgf-%C3%AE-pathways
#1
Nour M El-Etreby, Amany A Ghazy, Radwaa Rashad
BACKGROUND: Ovarian epithelial tumor (OET) is a silent disease of late diagnosis and poor prognosis. Currently treatment options are limited and patient response to treatment is difficult to predict so there is a serious need to delineate the real pathogenesis to predict tumour prognosis. Prohibitin (PHB) is an evolutionarily protein that regulates the cell cycle. TGF-β has been shown to be a positive and negative regulator of cellular proliferation and differentiation. The present study provides an overview on the role played by PHB1, TGF-β and LH in ovarian cancer...
April 20, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/28423547/genomic-imbalances-are-involved-in-mir-30c-and-let-7a-deregulation-in-ovarian-tumors-implications-for-hmga2-expression
#2
Antonio Agostini, Marta Brunetti, Ben Davidson, Claes G Tropé, Sverre Heim, Ioannis Panagopoulos, Francesca Micci
The High-mobility group AT-hook 2 protein (HMGA2) is involved in different processes during tumorigenesis. High expression levels of HMGA2 are found in various types of cancer, with recent studies highlighting the important role of miRNAs in the regulation of HMGA2 expression. We report a study of 155 ovarian tumors (30 sex-cord stromal tumors, 22 borderline tumors, and 103 carcinomas) analyzed for HMGA2 expression as well as the expression of two miRNAs targeting this gene, let-7a and miR-30c. We also evaluated the expression of the fragile histidine triad (FHIT) and lin28 homologues (LIN28A/B) genes which are known to be an enhancer of miR-30c expression and a repressor of let-7a, respectively...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416487/metabolic-markers-and-statistical-prediction-of-serous-ovarian-cancer-aggressiveness-by-ambient-ionization-mass-spectrometry-imaging
#3
Marta Sans, Kshipra M Gharpure, Robert Tibshirani, Jialing Zhang, Li Liang, Jinsong Liu, Jonathan H Young, Robert Dood, Anil K Sood, Livia Eberlin
Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality among gynecological cancers, developing rapidly and aggressively. Dissimilarly, serous borderline ovarian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical behavior. The underlying biological differences between HGSC and BOT call for accurate diagnostic methodologies and tailored treatment options, and identification of molecular markers of aggressiveness could provide valuable biochemical insights and improve disease management...
April 17, 2017: Cancer Research
https://www.readbyqxmd.com/read/28325358/seromucinous-ovarian-tumor-a-comparison-with-the-rest-of-ovarian-epithelial-tumors
#4
COMPARATIVE STUDY
Georgia Karpathiou, Celine Chauleur, Thomas Corsini, Melany Venet, Cyril Habougit, Freschia Honeyman, Fabien Forest, Michel Peoc'h
BACKGROUND: Seromucinous ovarian tumors are rare and not adequately described in the literature and this is especially true for seromucinous carcinomas. AIM OF THE STUDY: To describe histological and clinical features of these tumors in comparison with the rest of ovarian epithelial tumors. MATERIALS AND METHODS: Two hundred and forty one (241) ovarian tumors, borderline (n=92) or malignant (n=149), treated surgically without neoadjuvant chemotherapy, were examined...
April 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28277307/pathology-of-borderline-and-invasive-cancers
#5
REVIEW
Jaime Prat
Epithelial ovarian tumors are heterogeneous neoplasms primarily classified according to cell type. They are further subdivided into benign, borderline, and malignant (carcinomas), and this subdivision is very important as it correlates with behavior. Borderline ovarian tumors show epithelial proliferation higher than that seen in their benign counterparts and variable nuclear atypia; however, in contrast to carcinomas, there is no destructive stromal invasion, and their prognosis is much better. Ovarian carcinomas are the most common ovarian cancers and the most lethal gynecological malignancies...
October 3, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28248817/long-term-behavior-of-serous-borderline-tumors-subdivided-into-atypical-proliferative-tumors-and-noninvasive-low-grade-carcinomas-a-population-based-clinicopathologic-study-of-942-cases
#6
Russell Vang, Charlotte G Hannibal, Jette Junge, Kirsten Frederiksen, Susanne K Kjaer, Robert J Kurman
Ovarian serous borderline tumors (SBTs) have been the subject of considerable controversy, particularly with regard to terminology and behavior. It has been proposed that they constitute a heterogenous group of tumors composed, for the most part, of typical SBTs that are benign and designated "atypical proliferative serous tumor (APST)" and a small subset of SBTs with micropapillary architecture that have a poor outcome and are designated "noninvasive low-grade serous carcinoma (niLGSC)". It also has been argued that the difference in behavior between the 2 groups is not due to the subtype of the primary tumor but rather the presence of extraovarian disease, specifically invasive implants...
February 28, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28238418/foxa1-is-expressed-in-ovarian-mucinous-neoplasms
#7
Georgia Karpathiou, Melany Venet, Mousa Mobarki, Fabien Forest, Celine Chauleur, Michel Peoc'h
FOXA1 is a transcription factor essential for the binding and action of other transcription factors on the chromatin. It is the major regulator of endoderm differentiation. It has important roles in breast, prostate and endometrial cancer. It has never been studied in ovarian tumours. The aim of this study was to investigate its expression in ovarian epithelial neoplasms. A total of 195 primary ovarian epithelial borderline or malignant tumours were immunohistochemically studied for the expression of FOXA1...
April 2017: Pathology
https://www.readbyqxmd.com/read/28238382/frequency-of-papillary-tubal-hyperplasia-pth-salpingoliths-and-transition-from-adenoma-to-borderline-ovarian-tumors-bot-a-systematic-analysis-of-74-bot-with-different-histologic-types
#8
Lars-Christian Horn, Karolin Angermann, Bettina Hentschel, Jens Einenkel, Anne Kathrin Höhn
Borderline ovarian tumors (BOT) arise from cystadenomas and represent a transition step within the development of low-grade ovarian carcinomas (Type I tumors). That pathway mirrors the adenoma-to-carcinoma sequence known for colorectal cancer. It has been suggested that papillary tubal hyperplasia (PTH) and salpingoliths may be associated with the development of BOT. To evaluate the frequency of the presence of benign cystadenoma and its transition to BOT in a given patient as well as the presence of PTH and salpingoliths we re-valuated in 74 consecutive cases of BOT with different histologic types...
February 6, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28238354/optimal-primary-management-of-bulky-stage-iiic-ovarian-fallopian-tube-and-peritoneal-carcinoma-are-the-only-options-complete-gross-resection-at-primary-debulking-surgery-or-neoadjuvant-chemotherapy
#9
Vasileios D Sioulas, Maria B Schiavone, David Kadouri, Oliver Zivanovic, Kara Long Roche, Roisin O'Cearbhaill, Nadeem R Abu-Rustum, Douglas A Levine, Yukio Sonoda, Ginger J Gardner, Mario M Leitao, Dennis S Chi
OBJECTIVE: To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. METHODS: We retrospectively reviewed all patients with the aforementioned diagnosis who underwent PDS at our institution from 01/2001-12/2010. Those with disease of non-epithelial histology or borderline tumors were excluded. Clinicopathologic data were abstracted, and appropriate statistical tests were used...
April 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28228232/hormone-receptor-expression-profile-of-low-grade-serous-ovarian-cancers
#10
Marianna Buttarelli, Floriana Mascilini, Gian Franco Zannoni, Alessandra Ciucci, Enrica Martinelli, Flavia Filippetti, Giovanni Scambia, Gabriella Ferrandina, Daniela Gallo
OBJECTIVE: Low-grade serous ovarian carcinomas (LGSOCs) are a histological subtype of epithelial ovarian tumors, accounting for fewer than 5% of all cases of ovarian carcinoma. Due to the chemoresistant nature of this subtype a search for more effective systemic therapies is actively ongoing, hormonal therapy showing some degree of activity in this clinical setting. The present study ought to investigate the hormone receptor status of LGSOCs, as a strategy to provide molecular support for patient-tailored hormonal treatments...
February 20, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28184931/elf5-in-epithelial-ovarian-carcinoma-tissues-and-biological-behavior-in-ovarian-carcinoma-cells
#11
Hongchao Yan, Linglin Qiu, Xiaolei Xie, He Yang, Yongli Liu, Xiaoman Lin, Hongxiang Huang
The expression of E74-like factor 5 (ELF5) in epithelial ovarian carcinoma tissues and its effects on biological behavior in ovarian carcinoma cells were assessed in search for a new approach for gene treatment of epithelial ovarian carcinoma. RT-PCR technology was applied to detect the expression of ELF5 mRNA in epithelial ovarian carcinoma (n=49), borderline ovarian epithelial tumor (n=19), benign ovarian epithelial tumor (n=31) and normal ovarian tissues (n=40). Then, we transfected recombinant plasmid pcDNA3...
March 2017: Oncology Reports
https://www.readbyqxmd.com/read/28179304/imp3-expression-in-borderline-tumors-of-the-ovary
#12
Ahmed El-Balat, Nicole Sänger, Thomas Karn, Sven Becker, Uwe Holtrich, Zelal Muallem, Ruza Arsenic
BACKGROUND/AIM: Borderline ovarian tumors (BOTs) have a less aggressive behavior than invasive epithelial ovarian tumors. Still some patients relapse or succumb to disease. Molecular markers that reliably predict prognosis are lacking. Insulin-like growth factor II mRNA-binding protein (IMP3) has been suggested as a prognostic marker in colorectal, hepatocellular, and ovarian clear-cell carcinomas. MATERIALS AND METHODS: We analyzed the expression of IMP3 by immunohistochemistry in a cohort of 140 BOT and its association with histopathological features...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28166073/ovarian-tumors-pattern-of-histomorphological-types-a-10-years-study-in-a-tertiary-referral-center-and-review-of-literature
#13
A Ghosh, D Ghartimagar, S Thapa, B Sathian, R Narasimhan, O P Talwar
Background Ovarian cancer accounts for 6% of all cancers in females. Among cancers of female genital tract, the incidence of ovarian cancers ranks below only carcinoma of the cervix and the endometrium. Objective To find the frequency of different types of histomorphological types and their association with age, side and size distribution. Method This study is a hospital based retrospective study carried out in the Department of Pathology, Manipal Teaching Hospital over a time period from Jan. 2006 to Sep. 2015...
April 2016: Kathmandu University Medical Journal (KUMJ)
https://www.readbyqxmd.com/read/28160193/correlation-between-tumor-mesothelin-expression-and-serum-mesothelin-in-patients-with-epithelial-ovarian-carcinoma-a-potential-noninvasive-biomarker-for-mesothelin-targeted-therapy
#14
Tatsuya Hanaoka, Kosei Hasegawa, Tomomi Kato, Sho Sato, Akira Kurosaki, Akiko Miyara, Shoji Nagao, Hiroyuki Seki, Masanori Yasuda, Keiichi Fujiwara
BACKGROUND: The cell surface glycoprotein mesothelin is highly expressed in several malignant diseases. Normal mesothelin expression is limited to mesothelial cells lining the pleura, peritoneum, and pericardium, making it a biomarker and an attractive target for cancer therapy. METHODS: We investigated tumor mesothelin expression and serum mesothelin levels in patients with epithelial ovarian cancer or borderline tumors. In total, 161 patients selected from a previous prospective study were analyzed for tumor mesothelin expression using immunohistochemistry and serum mesothelin expression using enzyme-linked immunosorbent assay...
February 3, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28120491/ephb3-protein-is-associated-with-histological-grade-and-figo-stage-in-ovarian-serous-carcinomas
#15
Weiwei Gao, Qin Zhang, Yan Wang, Jiandong Wang, Shu Zhang
Eph (Erythropoietin-producing human hepatocellular carcinoma cell) is the largest subfamily of receptor tyrosine kinases. Eph receptors and their ephrin ligands are involved in embryonic development and physiological processes. Aberrant expression of Eph/ephrin may contribute to a variety of diseases including cancer. EphB3 is a member of Eph receptors and has been found to play roles in carcinogenesis of some types of human cancer. But, its expression and clinical significance in ovarian serous carcinoma have not been well investigated and are unknown...
February 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28101917/imaging-in-gynecological-disease-clinical-and-ultrasound-features-of-invasive-and-non-invasive-malignant-serous-ovarian-tumors
#16
F Moro, C Baima Poma, G F Zannoni, A Vidal Urbinati, T Pasciuto, M Ludovisi, M C Moruzzi, S Carinelli, D Franchi, G Scambia, A C Testa
OBJECTIVES: To describe clinical and ultrasound features of different subclasses of malignant serous ovarian tumors according to the WHO 2014 classification. METHODS: Patients with a histological diagnosis of borderline (BOT), non-invasive and invasive low grade serous carcinomas (LGSC) and high grade serous carcinoma (HGSC), who had undergone preoperative ultrasound examination, were retrospectively identified from two ultrasound centers. The masses were described using the terms of the International Ovarian Tumor Analysis group...
January 19, 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28041594/malignant-and-borderline-epithelial-ovarian-tumors-in-the-pediatric-and-adolescent-population
#17
Dimitrios Nasioudis, Michail Alevizakos, Kevin Holcomb, Steven S Witkin
OBJECTIVES: Malignant and borderline ovarian tumors of epithelial origin are rarely encountered among prepubertal girls and adolescents. The aim of this population-based study was to elucidate their clinicopathological characteristics and prognosis using a multi-institutional tumor registry. STUDY DESIGN AND OUTCOMES: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was accessed and a cohort of females aged <=19years old, diagnosed between 1988 and 2013 with a borderline ovarian tumor (BOT) or a malignant epithelial ovarian carcinoma (EOC) was accessed...
February 2017: Maturitas
https://www.readbyqxmd.com/read/28025670/ovarian-borderline-tumors-in-the-2014-who-classification-evolving-concepts-and-diagnostic-criteria
#18
REVIEW
Steffen Hauptmann, Katrin Friedrich, Raymond Redline, Stefanie Avril
Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. Since BOT were first identified >40 years ago, they have inspired controversies disproportionate to their incidence. This review discusses diagnostic criteria for the histologic subtypes of BOT, highlighting areas of diagnostic challenges, ongoing controversies, and changes in terminology implemented by the recent 2014 WHO Classification of Tumours of the Female Genital Organs...
February 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28006819/better-resource-utilisation-and-quality-of-care-for-ovarian-cancer-patients-using-internet-based-pathology-review
#19
S Kommoss, F Kommoss, J Diebold, S Lax, D Schmidt, A Staebler, A du Bois, J Pfisterer
BACKGROUND: The current literature indicates that a considerable number of patients in ovarian carcinoma clinical trials have histopathological diagnoses in conflict with inclusion criteria. It has been suggested that specialised pathology review prior to randomisation should become the standard procedure in study protocols. We hypothesised that our new, internet-based high-throughput infrastructure would be capable of providing specialised pathology review within 10 working days (w.d...
January 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/27987343/mature-cystic-teratoma-coexisting-with-clear-cell-carcinoma-in-the-ovary
#20
Koki Shimura, Mariko Matsumoto, Takuya Sugahara, Takuro Yamamoto, Nozomi Ogiso, Yoji Urata, Tomoharu Okubo
Mature cystic teratoma (MCT) is the most common benign ovarian tumor; clear-cell carcinoma (CCC) is a relatively common malignant ovarian tumor in Japan, but there are few reports on the coexistence of MCT and CCC. Here we report a case of simultaneous MCT and CCC in the ovary and review the relevant literature. The patient was a 49-year-old woman. A 5-cm MCT was found in the left ovary on initial gynecological examination, and she was referred to hospital for treatment because it was expanding. Magnetic resonance imaging showed a multilocular cystic tumor 16 × 10 × 9...
December 17, 2016: Journal of Obstetrics and Gynaecology Research
keyword
keyword
15094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"